Am. J. Respir. Crit. Care Med., Volume 162, Number 4, October 2000, S179-S184

Biotherapeutic Targets for the Treatment of Allergic Airway Disease

ANTHONY J. COYLE, CLARE M. LLOYD,^* and JOSE-CARLOS GUTIERREZ-RAMOS

Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts

T cells are critical mediators of inflammation and as such, their migration to inflammatory sites is a tightly controlled process involving a complex series of molecules expressed by a variety of cell types. As our appreciation of the mechanisms governing T cell surveillance, activation, differentiation, and subsequent homing to sites of inflammation has advanced, the opportunity to develop novel therapeutic agents that modulate the immune system has increased. Importantly, the possibility of specifically targetting subpopulations of effector cells raises the exciting potential for the development of novel agents that selectively modify the immune response to allergens, without resulting in generalized immune suppression.

This article has been cited by other articles:

				S. Gupta, B. Fuchs, S. Schulz-Maronde, A. Heitland, S. E. Escher, M. Mack, H.-C. Tillmann, A. Braun, W.-G. Forssmann, J. Elsner, et al. Intravascular inactivation of CCR5 by n-Nonanoyl-CC chemokine ligand 14 and inhibition of allergic airway inflammation J. Leukoc. Biol., March 1, 2008; 83(3): 765 - 773. [Abstract] [Full Text] [PDF]

				E.-B. Haddad, S. L. Underwood, D. Dabrowski, M. A. Birrell, K. McCluskie, C. H. Battram, M. Pecoraro, M. L. Foster, and M. G. Belvisi Critical Role for T Cells in Sephadex-Induced Airway Inflammation: Pharmacological and Immunological Characterization and Molecular Biomarker Identification J. Immunol., March 15, 2002; 168(6): 3004 - 3016. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580. [Full Text] [PDF]